Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.
Track and understand the impacts of market events for the companies, diseases, products, and targets you care about. Leverage reliable real-time data, analyst insights, and proprietary likelihood of approval analytics to predict and successfully navigate what lies ahead.
How it helps
Biomedtracker's exclusive likelihood of approval analyses highlight the "bottom line" impact of today’s news on your business. Our expert industry analysts draw insights from closely monitoring companies, clinical trials, deals, and regulatory meetings to capture and report on the most critical events.
How it works
Our data and analysts insights cut through the noise, so you not only know what happens, but understand why it matters for your business. Biomedtracker provides analysis of commercial, clinical, and regulatory activities as they happen, and present them to you via an easily searchable interface and automated alerts that keeps you at the top of your game.
Biomedtracker
28 Jul 2022
What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.
Biomedtracker, Meddevicetracker
23 May 2022
In this report, we cover catalysts from 31 drugs, devices, diagnostics, and deals expected to occur in the second quarter of 2022.
Topic Outlook
Biomedtracker, Meddevicetracker
08 Feb 2022
In pharma’s fast paced and continually evolving world, accurately anticipating the impact of events on the horizon is critical to your success.
Topic Business Strategies
Biomedtracker, Scrip
19 Mar 2021
Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.
Biomedtracker
03 Mar 2021
This is both an updated study of clinical drug development success rates from our 2016 report, and an expansion into the drivers of success with the addition of machine learning modeling to analyze the predictive factors contributing to drug development.
Topic Clinical Trials Drug Development Landscape Drug Pricing
Biomedtracker
By Daniel Chancellor 27 Nov 2020
Using M&A activity as a barometer for the overall health of the biopharma industry, we explore biopharma’s biggest deals of the past decade and examine what they may presage for the year to come. Dive into key insights on trends, M&A drivers, companies to watch, and more.
Topic M A
Biomedtracker
29 Apr 2020
Access this infographic which focuses on Gilead’s drug Remdesivir which currently shows the greatest promise for the likelihood of approval as a possible treatment to effectively treat the virus. The infographic highlights the drug summary and profile, the number of patients in each trial phase, and the history of events that have moved this product through the development process.
Topic Coronavirus FDA Drug Review
Biomedtracker
23 Mar 2020
In this infographic, we provide insight into key trials that are expecting developments in the approval process.
Topic Drug Approval Standards
Biomedtracker, Datamonitor Healthcare
27 Sep 2019
Take a longer-term look at key late-stage drugs projected to hit the market in 2020, including new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.
Biomedtracker
04 Sep 2019
Discover how creating custom company portfolios can help you overcome your toughest business challenges.
Topic Business Strategies
Datamonitor Healthcare, Biomedtracker
By Hardik Patel 15 Jul 2019
Pharma Intelligence presents an essential, free session during which industry analysts present their data-driven views about what to expect during the third quarter of 2019.
Meddevicetracker, Biomedtracker
05 Jul 2019
Staying on top of what’s going in the competitive Medtech market and getting a complete view of the competitive landscape and current market trends is critical to your business. Often, this essential information is fragmented and difficult to find, and gathering and synthesizing it is tedious and time consuming. Now, Biomedtracker puts this critical information at your fingertips, saving you time and effort. The new “Associated Products” section on relevant Biomedtracker Drug Profile pages shows you the full competitive landscape – including drugs, devices, and diagnostics – with a single search.
Topic Business Strategies Medtech
Biomedtracker, Datamonitor Healthcare
10 Apr 2019
3 – 9 December is National Influenza Vaccination Week, a national awareness week focused on highlighting the importance of influenza vaccination. In this free KOL Insight Interview excerpt from Datamonitor Healthcare, read what key opinion leaders from the UK and US in Infectious Diseases have to say about current efforts to combat influenza with seasonal influenza vaccines:
Biomedtracker, Meddevicetracker
10 Apr 2019
In this report, we cover catalysts from 23 drugs, devices and diagnostics expected to occur in early 2019.
Topic Approvals Drug Review Medtech
Biomedtracker
19 Oct 2018
Find out what’s in store for the remainder of 2018 with your copy of the Biomedtracker Q4 2018 Outlook Report Extract. This essential analysis of expected Q4 catalysts for 27 drugs is now available to you – for free. Drawn from the full report of the same name, this vital resource explores the likelihood of phase/PDUFA review success and overall Likelihood of Approval (LOA) based on a drug’s phase, drug class, and disease group.
Rachel specializes in
26+ years of experience
San Diego
Michael specializes in
22+ years of experience
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
